SAN FRANCISCO, Feb. 24, 2026/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in the TD Cowen 46th Annual Health Care Conference taking place March 2-4, 2026 in Boston and the 2026 Jefferies Biotech on the Beach Summit taking place March 9-11, 2026 in Miami.

• TD Cowen 46th Annual Health Care Conference in Boston on Wednesday, March 4, 2026 - webcast of the presentation to be available at 9:10 a.m. Eastern Time / 6:10 a.m. Pacific Time - link here
• 2026 Jefferies Biotech on the Beach Summit in Miami - March 9-11, 2026 - company management to be available for one-on-one meetings

The presentation will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.

If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Nektar is headquartered in San Francisco, California. For further information, visit https://www.nektar.com and follow us on LinkedIn.

For Investors:

Vivian [email protected]

Corey Davis, Ph.D.
LifeSci Advisors, LLC
[email protected]
212-915-2577

For Media:

Jonathan Pappas
LifeSci Communications
857-205-4403
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-two-investor-conferences-in-march-302696266.html

SOURCE Nektar Therapeutics